Lonquek (Lipegfilgrastim) for Stem Cell Mobilization of Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and Lymphoma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 23 Apr 2016
At a glance
- Drugs Lipegfilgrastim (Primary)
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Apr 2016 Last checked against ClinicalTrials.gov record.
- 19 Apr 2016 Planned End Date changed from 1 Jan 2020 to 1 Jul 2020.